OrbiMed’s AbCellera Biologics ABCL Stock Holding History

OrbiMed’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-250,000	Closed	-$2.66K	–	132
2022 Q2	$2.66K	Buy	+250,000	New	+$2.12M	0.05%	125

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OrbiMed's ABCL Position: Q3 2025 in Review

OrbiMed sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 3,344,568 shares — an estimated $11.5M sold.

OrbiMed first reported a position in ABCL in Q4 2020 and held it in 19 quarters. The position peaked at $338M in Q4 2020. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

OrbiMed reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
OrbiMed sold 3,344,568 AbCellera Biologics shares in Q3 2025, an estimated $11.5M.
OrbiMed first reported a position in AbCellera Biologics in Q4 2020 and held it in 19 quarters.
OrbiMed's AbCellera Biologics position peaked at $338M in Q4 2020.
141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.